Connect with us

Business

Moderna Stock Jumps as Biotech Rakes in Revenue for Covid Vaccine – Barron’s

Published

on

post featured image

Modernas
efforts to develop the first Covid-19 vaccine led to a big jump in third-quarter research and development costs, as well as soaring revenue.The Cambridge, Mass.-based biotech company, which doesnt yet have a commercial product but is among the companies chasing approval for a coronavirus vaccine, reported third-quarter earnings Thursday morning. It had a loss of 59 cents a share on revenue of $157.9 million. Revenue, which was boosted mostly by grants for Covid vaccine development, was…

Click here to view the original article.